Solid glp-1 derivative compositions for oral administration
US-11167014-B2 · Nov 9, 2021 · US
Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid
US11622996B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11622996-B2 |
| Application number | US-201917053511-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 6, 2019 |
| Priority date | May 7, 2018 |
| Publication date | Apr 11, 2023 |
| Grant date | Apr 11, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates to pharmaceutical compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. The invention further relates to processes for the preparation of such compositions, and their use in medicine.
First claim
Opening claim text (preview).
The invention claimed is: 1. A composition comprising i) semaglutide, ii) sodium salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid (SNAC), and iii) nicotinamide, wherein the nicotinamide increases the solubility of SNAC at least 5-fold when the solubility is measured at a concentration of 200 mg/ml of the nicotinamide at a pH of 6. 2. The composition according to claim 1 , wherein the ratio of the SNAC/nicotinamide (w/w) (w/w) is 0.5-10. 3. The composition according to claim 2 , wherein the ratio of the SNAC/nicotinamide (w/w) is 0.5-8. 4. The composition according to claim 3 , wherein the ratio of the SNAC/nicotinamide (w/w) is 0.5-5. 5. The composition according to claim 4 , wherein the composition further comprises a lubricant selected from the group consisting of magnesium stearate and glyceryl dibehenate. 6. The composition according to claim 3 , wherein the composition further comprises a lubricant selected from the group consisting of magnesium stearate and glyceryl dibehenate. 7. The composition according to claim 1 , wherein the composition further comprises a lubricant. 8. The composition according to claim 7 , wherein a unit dosage is: i) 0.1-30 mg of the semaglutide, ii) 50-600 mg of the SNAC, iii) 20-200 mg of the nicotinamide, and iv) 0-10 mg of the lubricant. 9. The composition according to claim 8 , wherein the lubricant is selected from the group consisting of magnesium stearate and glyceryl dibehenate. 10. The composition according to claim 7 , wherein the lubricant is selected from the group consisting of magnesium stearate and glyceryl dibehenate. 11. The composition according to claim 1 , wherein the composition is a solid composition. 12. The composition according to claim 1 wherein the composition is a pharmaceutical composition suitable for oral administration.
Assignees
Inventors
Classifications
- A61K9/1617Primary
Organic compounds, e.g. phospholipids, fats · CPC title
Organic compounds, e.g. phospholipids, fats · CPC title
Anorexiants; Antiobesity agents · CPC title
Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones · CPC title
- A61K38/26Primary
Glucagons · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11622996B2 cover?
- The invention relates to pharmaceutical compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. The invention further relates to processes for the preparation of such compositions, and their use in medicine.
- Who is the assignee on this patent?
- Novo Nordisk As
- What technology area does this patent fall under?
- Primary CPC classification A61K9/1617. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Apr 11 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).